AN2 Therapeutics shares are trading lower after the company announced that it will discontinue its EBO-301 study following topline results from its Phase 2 part of the study in treatment-refractory patients with MAC lung disease.
Portfolio Pulse from Benzinga Newsdesk
AN2 Therapeutics shares are trading lower after the company announced the discontinuation of its EBO-301 study following topline results from its Phase 2 part of the study in treatment-refractory patients with MAC lung disease.
August 09, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AN2 Therapeutics shares are trading lower after the company announced the discontinuation of its EBO-301 study following topline results from its Phase 2 part of the study in treatment-refractory patients with MAC lung disease.
The discontinuation of the EBO-301 study is a significant setback for AN2 Therapeutics, as it indicates that the treatment did not meet the desired outcomes in Phase 2. This negative development is likely to impact investor sentiment and result in a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100